Revenue YoY
-29.12%
Operating Income YoY
+8.50%
Net Income YoY
+4.90%
Net Margin Δ
-3666 bps
Net income bridge for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $163M+4.90%
Profit bridge breakdown for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | -$3.36B | — |
| Revenue | -$914M | -560.7% |
| Cost of Revenue | -$1.08B | -660.1% |
| Operating Expenses | $2.31B | +1,415.3% |
| Other Income / Expense | -$49M | -30.1% |
| Income Tax | -$105M | -64.4% |
| Net Loss | -$3.19B | — |
- Prior Net Income-$3.36B
- Revenue-$914M
- Cost of Revenue-$1.08B
- Operating Expenses$2.31B
- Other Income / Expense-$49M
- Income Tax-$105M
- Net Loss-$3.19B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.